Latest Healthcare News

Invex Therapeutics Ltd has had its trading suspension lifted following an announcement of new board and officer appointments, signaling a fresh chapter for the biotech company.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

Compumedics has landed a $4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, pushing total MEG sales in China to $25 million and reinforcing its leadership in the Asian neuro-imaging market.

Algorae Pharmaceuticals has launched AlgoraeOS Version 2, a major AI platform upgrade that surpasses leading models including those from Google DeepMind, promising to accelerate drug-combination discovery.

Integral Diagnostics has appointed Jason Martinez as its new CEO, set to lead the company’s growth and innovation efforts starting in 2026. Martinez brings over two decades of diagnostic imaging leadership experience, promising a strategic focus on expansion and operational excellence.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

Invex Therapeutics Ltd has been suspended from trading on the ASX due to a failure to maintain the minimum number of directors required by law. The suspension will remain until the company rectifies its governance structure and complies with listing rules.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Epsilon Healthcare reports a strong rebound with a 73% revenue increase in the June quarter, driven by contract manufacturing and new pharmacy operations. The company is emerging from restructuring with renewed financial strength and growth prospects.

Epsilon Healthcare has commenced operations of its new pharmacy division and extended a key loan facility, signaling a strategic pivot towards integrated healthcare and financial stability after recent restructuring.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.

AVITA Medical reported an 18% revenue increase in Q3 2025 driven by new product launches and deeper market penetration, while continuing to face net losses and credit covenant challenges. The company also announced a CEO departure and interim leadership appointment.